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Purpose: To evaluate the significance of fractionated 
administration of thalidomide combined with γ-ray 
irradiation in terms of local tumor response and lung 
metastatic potential, referring to the response of intratumor 
quiescent (Q) cells. 
Materials/methods: B16-BL6 melanoma tumor-bearing 
C57BL/6 mice were continuously given 5-bromo-2’-
deoxyuridine (BrdU) to label all proliferating (P) cells. The 
tumor-bearing mice then received γ-ray irradiation after 
thalidomide treatment through a single or 2 consecutive daily 
intraperitoneal administrations up to a total dose of 400 
mg/kg in combination with an acute hypoxia-releasing agent 
(nicotinamide, 1,000 mg/kg, intraperitoneally administered) 
or mild temperature hyperthermia (MTH, 40 centigrade for 
60 minutes). Immediately after the irradiation, cells from 
some tumors were isolated and incubated with a cytokinesis 
blocker. The responses of the Q and total (= P + Q) cell 
populations were assessed based on the frequency of 
micronuclei using immunofluorescence staining for BrdU. In 
other tumor-bearing mice, 17 days after irradiation, 
macroscopic lung metastases were enumerated. 
Results: Thalidomide raised the sensitivity of the total cell 
population more remarkably than Q cells in both single and 
daily administrations. Daily administration of thalidomide 
elevated the sensitivity of both the total and Q cell 
populations, but especially the total cell population, 
compared with single administration. Daily administration, 
especially combined with MTH, decreased the number of lung 
metastases. 
Conclusions: Daily fractionated administration of thalidomide 
in combination with γ-ray irradiation was thought to be more 
promising than single administration because of its potential 
to enhance local tumor response and repress lung metastatic 
potential. 
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Purpose: The Malthus model is an evidence based simulation 
of radiotherapy demand in England, which was designed to 
estimate radiotherapy utilisation at local and national level, 
in order to assist in planning of radiotherapy services. The 
model utilised cancer registration data from the national 
cancer registration service, together with predictions of 
population growth from the Office of National Statistics, and 
cancer incidence projections. We present the results of an 
updated model that utilises the latest population projection 
estimates, and cancer incidence data. 
Materials and Methods: Base data on cancer registration was 
provided by the National Cancer Intelligence Network, 
broken down by disease site, local Clinical Commissioning 
Groups (CCGs), age and sex. Equivalent population data was 
sourced from the Office for National Statistics. These two 
datasets were combined with data from 2,000 evidence-
based clinical decisions, covering 22 different cancer sites. 
Clinical practice was peer-reviewed by over 100 British 
oncologists and at a national forum. An updated cancer 
incidence projection model and population projection model 
were also used to enable annual demand predictions up to 
2035. 
Results: The Malthus model estimates that the access rate for 
radiotherapy in England in 2015 should be 40.5% with a 
fraction burden of approximately 47,500 fractions per million 
population. To highlight how different regions within a 
country can be, Table 1 displays two regions and the England 
average for comparison. The predicted demand for 
radiotherapy is also increasing for England. Over the next few 
year the predicted fractions per million will increase by 0.9% 
per year, this will increase to 1% per year in 2020 and is 
expected to hit 1.1% per year by 2026.  
 
 
 
Conclusions: The Malthus model with updated cancer 
incidence data suggests a radiotherapy utilisation rate of 
40.5%, with a predicted annual increase of fractions per 
million of around 1% per year. Whilst the observed rates of 
radiotherapy utilisation still lag behind the model’s 
predictions, the observed activity increases in England (from 
the Radiotherapy Data Set) over the last 3 years exceed the 
rate of rise in predicted demand. Customised simulations for 
individual regions, such as what Malthus can do, allows local 
cancer profiles to be taken into account for more accurate 
current and future demand predictions. The customisability 
also allows for simulations looking at the impact of new 
technology, such as MRI Linac and Proton therapy, and data 
from other countries can be incorporated as well.  
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Purpose: MRI-linacs will enable 4D image-guided radiotherapy 
and require accurate MR visible and compatible dosimeter 
systems for verification. 
Methods: Motion-tracking utilising a MagicPlate (M512) silicon 
array dosimeter capable of high resolution dosimetry 
(Petasecca, 2015) (figure 1a,b)has been modified for purpose 
of MR imaging during dynamic detector-tracking (i.e. so 
named ‘MR guided dynamic dosimaging’). The detector was 
tested for MRI-safety and functionality without irradiation in 
a 1T fringe field of 3T Siemens Skyra MRI. As solid water can 
not be visualized on MRI a tissue-equivalent, gel-water 
phantom (CIRS® Computerized Imaging Reference Systems 
Inc. VA, USA), providing signal for detector and fiducial 
visualisation, was utilised to enable MR imaging (fast spin 
echo sequence).  
Results: MR images of a non-powered detector system 
demonstrated detector visualization (see figure 1c). Detector 
movements approximating breathing were also acquired 
during dynamic MRI acquisition (fast gradient echo), showing 
that fiducial markers could be visualised when placed on a 
passive device and tracked. The detector functioned at the 
1T bore entry position to simulate the magnetic field of our 
impending MR linac whilst a water phantom was imaged 
simultaneously at the mid-bore 3T position, with noise (see 
figure 1d) seen due to detector RF interference being 
reduced by aluminium foil shielding of the device and cables 
(figure 1e).  
Conclusions: The current MRI-guided dynamic dosimaging set-
up has been demonstrated to be successful in detector 
visualisation and tracking with a non-powered detector. 
Noise reduction has been achieved with the detector in 
operational mode. A MRI-compatible motion platform will be 
paired with M512. These measurements will be compared to 
acquisition in MRI-linac magnetic fields on the MRI-linac 
device being installed at the Ingham Institute in Australia. 
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Figure 1: (a) M512 array, (b) M512 dosimetry acquisition of 
1x1cm2 field, (c) Passive M512 MR imaged at 3T, blue circles 
indicate fiducials (d) MR image of water phantom imaged 
without dosimeter noise suppression, (e) MR image of water 
phantom imaged with dosimeter noise suppression. 
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Purpose: There is an important need to improve the 
effectiveness of radio-chemotherapy (RTCT) for cervical 
cancer. These tumors recruit myeloid cells from the bone 
marrow via the CXCL12/CXCR4 pathway, which in turn 
influence vascular function and radiotherapy response. The 
objective of this study was to explore combined treatment 
with Plerixafor (a CXCL12/CXCR4 inhibitor) and standard 
RTCT on primary tumor control and the development of 
metastases, using orthotopic primary xenografts derived 
directly from patients with cervical cancer. 
Materials/Methods: Two primary cervix xenografts (OCICx13 
and OCICx20) were grown in the cervices of immune deficient 
mice.  These tumor models have been shown to mirror the 
clinical and biological behavior of cervical cancer in patients. 
To simulate clinical treatment, image-guided radiotherapy 
(30 Gy in 15 daily fractions) and concurrent weekly cisplatin 
(4 mg/kg) were administered, with or without Plerixafor (5 
mg/kg/day). The primary endpoints were tumor growth 
delay, the frequency of lymph node metastases and animal 
survival. Chemokine expression and neutrophil recruitment 
were evaluated by immunohistochemistry. Acute gut toxicity 
was assessed using the crypt cell assay. Blood and normal 
organs were examined for late toxicity. 
Results: The combination of RTCT and Plerixafor produced 
substantial tumor growth delay, reduced metastases and 
improved survival compared to standard RTCT alone in 
patient-derived xenograft models. There was a reduction in 
chemokine signaling (CXCL12/CXCR4) and myeloid cell 
infiltration (GCSF, CD11b) with combination treatment 
compared to RTCT alone. There was no effect of Plerixafor 
on acute GI toxicity, nor were there changes in blood counts 
or organ morphology to indicate increased late hematological 
or normal tissue toxicity.  
Conclusion: This preclinical study demonstrates that the 
addition of Plerixafor to standard RTCT for cervical cancer 
improves local tumor control and reduced metastases with no 
increase in toxicity. Plerixafor is commercially available for 
other indications, which will facilitate translation of these 
findings to phase I/II clinical studies. 
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Curative 3D standard external beam radiotherapy (EBRT) for 
prostate cancer has been able to improve disease control 
with dose escalation during the last 15 years though against 
the token of significant toxicity. Exploring changes in 
fractionation, doses-distribution optimization with modulated 
RT, and reducing CTV-PTV safety margins due to off- or on-
line imaging before or during irradiation, may be alternatives 
worth to be implemented in order to reach the highest 
possible toxicity-free cure rates. 
Accurate imaging helping to better define the irradiation 
target/s (e.g., multiparametric MRI, PET-CT/MRI, SPECT); 
modulated EBRT optimizing the dose distribution; and image 
guided RT (e.g., kV imaging, CBCT, fiducial markers, 
transponders, endorectal balloons, recto-prostatic spacers) 
controlling for patient repositioning and organ motion are 
presently available allowing the implementation of high 
precision treatment techniques.  
Biomathematical modeling has helped to better understand 
the very special dose-response relationships of EBRT on 
prostate cancer concerning fractionation sensitivity (low α/β 
value), overall treatment time (tumor cell repopulation 
kinetics), and fraction delivery time (potential biological 
effective dose modifier). All these factors are rather 
suggestive that prostate cancer patients, especially those 
with low- or intermediate-risk disease, can be better treated 
with “more” dose/fraction, “less” number of fractions, and a 
“shorter” time protraction and delivery time per fraction. 
Two opposed modalities conceived to deliver large doses in 
few fractions are either stereotactic body RT (SBRT) or high-
dose rate brachytherapy (HDR-BT) given alone or as a boost. 
The latter procedure may be limited by dose inhomogeneities 
and geographical misses. Even a small underdosage of the 
target or a heterogeneous dose-rate delivery may have a 
negative influence on outcome. This seems to be especially 
determinant for tumors with very low α/β values as it is the 
case for prostate cancer. Thus, SBRT may be theoretically 
more advantageous because the radiobiological reliability of 
a homogeneous dose distribution compared to HDR-BT, 
besides being less invasive and probably less costly.  
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Proton radiotherapy provides a promising and emerging 
treatment approach for cancer patients. However, 
understanding of the differences in terms of DNA damage and 
cell proliferation post-proton irradiation is relatively poor. 
The purpose of this study was to evaluate DNA damage 
induced by proton beams using various cytogenetic and 
molecular methods. 
